ARTIMPLANT INTERIM REPORT JANUARY - JUNE 2009

ARTIMPLANT INTERIM REPORT JANUARY - JUNE 2009

Västra Frölunda, Sweden, August 5, 2009

• Net revenue for the second quarter amounted to SEK 7.9 million (3.1) and for
the first six months SEK 12.8 million (5.2)*
• The net loss for the second quarter totaled SEK 4.1 million (6.2) and for the
first six months SEK 8.6 million (12.3)   
• Earnings per share for the second quarter amounted to SEK -0.07 (-0.10) and
for the first six months SEK -0.14 (-0.21)   
• Sales of Artelon® Spacer for the second quarter totaled SEK 4.7 million (2.4)
and for the first six months SEK 8.2 million (3.7) 
• Sales of Artelon® Tissue Reinforcement for the second quarter amounted to SEK
3.1 million (0.6) and for the first six months SEK 4.4 million (1.4)   
• The first patient has been enrolled in a clinical investigation of treatment
of osteoarthritis in the lumbar facet joints using an Artelon® implant
• The first dogs in the USA underwent surgery using Artelon® CCL for cruciate
ligament injuries

N.B. This is a translation from Swedish. The Swedish version shall always take
precedence.

Artimplant will hold a telephone conference by reason of this report on August
5, 2009 at 3 pm (GMT+1). For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year

For further information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Further information is available at www.artimplant.com. To subscribe to future
press releases please go to
www.artimplant.com/investors-media/subscribe-to-press-releases.html

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral surgery and veterinary
medical applications. 

Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in
the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on August 5, 2009 at 2:00 pm (GMT+1).